On April 25, Terri Nataline and Fran Zipp participated in a summit focusing on global strategies for Indian pharmaceutical companies, the Annual Global Pharma Regulatory Summit, in Mumbai, India. This summit brings together global regulators who shared their knowledge about complying with international regulatory guidelines for manufacturing and exporting pharmaceuticals. Terri Nataline, Principal Consultant, presented in 2 sessions dealing with US FDA specific requirements, on Refuse-to-Receive Standards and Stability Testing for ANDA Submissions, while Fran Zipp, President and CEO, presented on US FDA Audit Preparation. This three-day summit was filled with presentations from former investigators and directors at FDA and MHRA, representatives from the Indian pharmaceutical industry, including those that specialize in servicing the needs of developing countries/regions (Latin America, Sri Lanka, Russia, Southeast Asia, and the Gulf Cooperation Council countries [Saudi Arabia, Kuwait, UAE, Qatar, Bahrain, and Oman]).